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A B S T R A C T
Rationale: Many high-burden countries are scaling-up Xpert MTB/RIF using a hub-and-spoke model. We eval-
uated the quality of care for patients undergoing TB evaluation at microscopy centers (spokes) linked to Xpert
testing sites (hubs) in Uganda.
Objectives: To characterize the extent to which patients were receiving care in accordance with international and
national guidelines.
Methods: We conducted a prospective cohort study of all adults with presumptive pulmonary TB at 24 health
centers linked to Xpert testing sites. Health center staff photographed TB registers, and uploaded photos to a
secure server bi-weekly. We assessed the proportion of patients (1) initiating testing; (2) completing testing; and
(3) treated for confirmed TB within 14 days.
Measurements and Main Results: Between January to December 2017, 6744 patients underwent evaluation for
pulmonary TB. Only 1316 patients had sputum referred for Xpert testing, including 1075/3229 (33.3%) people
living with HIV and 241/3515 (6.9%) without HIV. Of 119 patients confirmed to have TB by Xpert testing, 44
(36%) did not initiate treatment. There were significant losses along the entire diagnostic cascade of care, with
only 5330/6744 (79.0%) patients having samples referred for sputum-based testing, 2978/5330 (55.9%) pa-
tients completing recommended testing if referred, and 313/418 (74.9%) patients initiating treatment within 14
days if confirmed to have TB.
Conclusions: Although coverage of Xpert testing services across Uganda is high, the quality of care delivered to
patients undergoing TB evaluation remains poor. Further research is needed to identify health system inter-
ventions to facilitate uptake of Xpert testing and high-quality care.
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1. Introduction
According the World Health Organization (WHO), tuberculosis (TB)
is now the leading cause of death from an infectious disease worldwide.
An estimated 10.4 million people developed TB and 1.7 million died of
the disease in 2016, which reflects an annual 2% decline in incidence
and 3% decline in mortality [1]. Yet these estimates fall short of the
progress needed to meet the ambitious targets of 95% reduction in TB
mortality and 90% reduction in TB incidence by 2035 set forth by the
End TB Strategy [2]. To accelerate progress, the End TB Strategy calls
for enhanced implementation of current and novel tools emerging from
the pipeline, including new diagnostics.
Xpert MTB/RIF® (Xpert), the first rapid molecular test for TB en-
dorsed by the WHO, has been rapidly scaled-up in high burden coun-
tries since it was first introduced in 2010. Xpert is a semi-automated,
cartridge-based molecular assay for diagnosis of pulmonary TB and
detection of rifampicin resistance, and it is more sensitive than sputum
smear microscopy [3]. The WHO now recommends Xpert as the initial
diagnostic test for pulmonary TB in countries with high HIV prevalence
and, where feasible, as a follow-on test for those with a negative smear
microscopy result [4]. From 2010 to 2016, 29,865 Xpert modules and
23.1 million cartridges have been procured by low- and middle-income
countries eligible for concessional pricing [5]. In addition, 28 of 48
high-burden TB, TB/HIV, or multidrug-resistant (MDR) TB countries
have adopted national algorithms with Xpert as the initial diagnostic
test for presumptive TB patients [6].
Although coverage of Xpert testing has increased dramatically, im-
portant questions related to Xpert implementation remain unanswered,
including uptake in routine care and impact on quality of care for pa-
tients with presumptive TB. To address these questions, we collaborated
with the Uganda National Tuberculosis and Leprosy Programme (NTLP)
to evaluate the quality of care for patients undergoing TB evaluation at
24 health centers in Uganda that are linked to Xpert testing sites. Our
objective was to characterize the extent to which patients were re-
ceiving care in accordance with national and international guidelines.
2. Methods
2.1. Study context
Uganda has been a leader in scaling up Xpert testing. As of
December 2016, Uganda had procured 526 GeneXpert modules and
353,790 Xpert cartridges [5]. Since the majority of health centers in
Uganda with TB diagnostic units lack adequate infrastructure to per-
form Xpert testing, the Uganda NTLP established a specimen-referral
system in 2012, linking community-level TB microscopy centers
(spokes) to regional- or district-level laboratories with GeneXpert de-
vices (hubs) [7]. Sputum samples are transported from the spokes to the
hubs via motorcycle (boda-boda) and results are returned the next time
samples are collected. During the study period, Uganda NTLP guide-
lines, in accordance with the International Standards for TB Care
(ISTC), recommended that Xpert be performed as a first-line test for
high-risk groups including people living with HIV (PLHIV) [8,9].
2.2. Study setting and population
We identified potential study health centers by reviewing 2015
NTLP TB testing and treatment data for all community-level TB mi-
croscopy units (spokes) that were linked to Xpert testing sites (hubs)
through the NTLP Xpert referral network. We included health centers
that: (1) used sputum smear microscopy as the primary method of TB
diagnosis; (2) participated in NTLP-sponsored external quality assur-
ance for sputum smear microscopy; and (3) referred sputum samples to
a district or regional health facility for Xpert testing. We excluded
health centers that (1) performed sputum smear microscopy on less
than 150 patients per year and (2) diagnosed less than 15 smear-
positive TB cases per year. We worked with the Uganda NTLP to select
24 health centers from among those meeting eligibility criteria, ex-
cluding ones for which the District Health Officer did not consent to
participate in the study. The 24 health centers referred sputum samples
to a total of 17 Xpert testing hubs (see Supplementary Fig. 1).
We included data on all patients evaluated for pulmonary TB at the
24 health centers between January and December 2017. Patients were
excluded if they (1) had sputum collected for monitoring of response to
anti-TB therapy; (2) had sputum collected as part of active, community-
based case finding (e.g., contact tracing, community outreach cam-
paign); (3) had a documented prior history of TB treatment (e.g., reason
for Xpert testing or TB treatment marked as treatment failure, relapse,
or treatment after loss to follow-up); (4) were referred to a study health
center for TB treatment after a diagnosis was established elsewhere; (5)
were started on treatment for presumptive extra-pulmonary TB only; or
(6) were less than 18 years old.
The study was approved by the University of California San
Francisco Committee on Human Research, the Makerere University
School of Medicine Research Ethics Committee, and by the Uganda
National Council for Science and Technology. The requirement for in-
formed consent was waived.
2.3. Study procedures
2.3.1. TB guideline training
A half-day refresher training on Uganda NTLP guidelines on TB di-
agnosis and treatment co-chaired by the District TB and Leprosy
Supervisors and an NTLP/NTRL representative was held at each health
center one to three months prior to the start of patient data collection. All
health center staff directly involved in the care of patients with pre-
sumptive TB were invited to participate. Health center staff were also
trained on how to complete TB registers, with emphasis on completion of
frequently missing fields. In addition, Xpert testing hubs linked to study
health centers were visited, and laboratory staff were provided with re-
fresher training on GeneXpert device maintenance and operation.
2.3.2. Patient-level data collection
We collected patient-level demographic and clinical information
from all health centers using existing data sources. During the health
center visit to review guidelines, we trained two health center staff (one
primary, one backup) identified by the health center director to take
photos of data sources using a camera-equipped smartphone. They were
instructed to upload the photos to a central secure server every two
weeks for the duration of the study using Research Electronic Data
Capture (REDCap) mobile software. Routine data sources included (1)
NTLP Presumptive TB, Laboratory and Treatment registers and (2)
Xpert laboratory requisition forms. Study staff reviewed each batch of
photos from each health center for completeness and accuracy, and
then extracted individual-level patient data using standardized REDCap
forms (see Supplementary Materials 2 for details). Data extracted in-
cluded demographics, HIV and ART status, TB test results and dates,
and TB treatment date. If missing information or logical inconsistencies
were identified, we first consulted the original data photographs, and
then we phoned the health centers after every 2-week period of data
extraction to resolve discrepancies and uncertainties. In addition to the
primary data sources, we extracted Xpert testing data from the national
GxAlert server hosted at NTLP to ensure complete capture of Xpert test
results and reviewed pre-ART and ART registers to verify ART status for
any patient living with HIV who was missing ART information. Finally,
we checked other data sources (e.g., clinic registration logbooks) as
needed to attempt to track down key information missing from primary
sources during scheduled quarterly health center visits, including
treatment status for all patients. If a patient was identified as RIF-re-
sistant by Xpert, study staff called the referral MDR-TB treatment center
to determine whether the patient was evaluated, if additional testing
was performed, and/or if treatment was initiated.
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Fig. 1. Patient Flow Diagram. Of 6869 adults identified
at 24 health centers through review of the TB-related
data sources, 6744 (98.2%) with presumptive pul-
monary TB were included in the analysis. TB treatment
was initiated 465 of 574 (81.0%) patients with a con-
firmed TB diagnosis and 207 of 6744 (3.1%) without a
positive sputum smear or Xpert result. Of the 207 pa-
tients treated empirically, 20 (9.7%) were Xpert-nega-
tive, 91 (44.0%) were smear-negative, and 96 (46.4%)
were not tested.
Fig. 2. Cumulative proportion initiating TB treatment, by test. Among the 465 patients who initiated TB treatment, median time-to-treatment was 0 days (IQR 0–1)
for the 390 patients diagnosed via smear microscopy and 2 days (IQR 0–7) for the 75 patients diagnosed via Xpert. The cumulative proportion starting treatment by 7
days (94.1% vs. 75.0%, p < 0.001) and 14 days (97.1% vs. 84.4%, p < 0.001) was higher for patients diagnosed via smear microscopy.
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2.4. Study outcomes
We defined a presumptive TB patient to be any eligible adult listed
in any NTLP TB register, Xpert laboratory requisition form, or GxAlert
database. Three quality indicators were assessed, each representing an
ISTC guideline-recommended step along the diagnostic cascade of care
for patients with presumptive TB(9): (1) proportion of presumptive TB
patients referred for sputum-based TB testing (i.e., had sputum col-
lected for smear or Xpert testing); (2) proportion of patients referred
who completed testing per Uganda NTLP guidelines (i.e., one valid
Xpert result or, if HIV-negative, one positive or two negative smear
results); and (3) proportion of microbiologically-confirmed TB patients
who were initiated on TB treatment within 14 days of presenting to the
health center. In addition, we evaluated a summary metric of the entire
TB diagnostic process: the proportion of presumptive TB patients who
were evaluated in accordance with ISTC recommendations (i.e., had
samples referred for testing, completed testing, and treated within 14
days if test-positive).
2.5. Statistical analysis
All analyses were carried out using STATA 14 (StataCorp LP,
College Station, TX). Xpert utilization and quality indicators were as-
sessed using binomial regression with robust standard errors accounting
for clustering by health center to give overall proportions and 95%
confidence intervals (CI) and proportions by month. Binomial regres-
sion was also used to assess differences in indicators proportions by test
type. Time-to-treatment were reported overall and by test type using
median and interquartile range (IQR), and we plotted a Kaplan–Meier
failure function to visually assess cumulative proportion of patients
initiating treatment by test.
3. Results
3.1. Patient characteristics
Of 6869 adults identified across the TB-related data sources, 125
(1.8%) were excluded from the analysis: 102 (1.5%) follow-up patients,
13 (0.2%) patients with extra-pulmonary TB only, 2 (0.03%) patients
identified as having rifampin resistance on Xpert testing, and 8 (0.1%)
patients identified through community-based active case finding cam-
paigns. Thus, 6744 (98.2%) adults with presumptive pulmonary TB at
the 24 health centers were included (median across the 24 clinics of
231, interquartile range [IQR] 186–321) (Fig. 1). The median age was
38 years (IQR 28–50), 3381 (50.1%) were female, and 3229 (47.9%)
were documented as being HIV seropositive. TB was confirmed in 574
(8.5%) patients, of whom 465 (81.0%) were initiated on TB treatment.
In addition, 207 of 6744 (3.1%) patients without microbiologic con-
firmation were treated for TB (Fig. 1).
Fig. 3. Quality of TB diagnostic evaluation (January–December 2017). The table displays the proportion of adults with presumptive TB at 24 health centers who
completed each step of the diagnostic process, generated through binomial regression models adjusted for clustering by health center. Overall, 79.0% of presumptive
TB patients had samples referred for sputum-based testing, 55.9% completed testing if referred, and 74.9% were treated within 14 days if TB was microbiologically-
confirmed. The proportion completing all steps in accordance with the International Standards for TB Care was 42.6%. Compared to patients with samples referred
for smear microscopy, patients with samples referred for Xpert testing were more likely to complete testing (97.7% vs 42.3%) but less likely to initiate treatment
within 14 days if test results were positive (52.9% vs. 83.6%).
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3.2. Xpert utilization and outcomes
Of the 6744 adults with presumptive TB, 1316 (19.5%, 95% CI
18.6–20.5%) had samples referred for Xpert testing, including 1075 of
3229 (33.3%, 95% CI 31.5–34.8) with and 241 of 3515 (6.9%, 95% CI
6.0–7.7) without documented HIV infection. Uptake of Xpert testing
was low throughout the study period, with as few as 10.5% and as
much as 29.4% having samples referred for Xpert testing during the
study period. There was no increasing trend over time (p < 0.05, chi-
squared test for trend). Xpert was requested as the first-line test for only
81 of 6744 (1.2%) patients overall and 60 of 3229 (1.9%) patients with
HIV infection. Of the 119 patients confirmed to have TB by Xpert
testing, 75 (63.0%) were initiated on treatment overall and 63 (52.9%)
within 14 days. Median time-to-treatment was longer for patients
confirmed to have TB by Xpert testing (2 days, IQR 0–7) compared to
smear microscopy (0 days, IQR 0—1). The cumulative proportion
started on treatment was lower at both 7 days (75.0% vs. 94.1%,
p < 0.001) and 14 days (84.4% vs. 97.1%, p < 0.001) for patients
confirmed to have TB by Xpert testing (Fig. 2).
3.3. Quality of TB diagnosis
3.3.1. Referral for sputum-based TB testing
Of the 6744 patients with presumptive TB, 5330 had samples re-
ferred for sputum-based testing (i.e., had sputum collected for onsite
sputum smear microscopy and/or hub-based Xpert testing). The pro-
portion of patients with samples referred for testing was 79.0% (95%
CI: 75.2–83.0%) overall (Fig. 3) and ranged across health centers from
58.7% to 92.0% (Fig. 4). The proportion of patients with samples re-
ferred for testing ranged across months from 70.3% to 84.3% (Fig. 5).
3.3.2. Completion of TB testing
Of the 5330 patients with samples referred for testing, 2978 (55.9;
95% CI: 49.0–63.7%) completed testing per Uganda NTLP guidelines,
ranging across health centers from 20.9% to 80.8% (Figs. 3 and 4). The
proportion of patients completing testing ranged across months from
41.9% to 66.5% (Fig. 5).
3.3.3. Treatment initiation within 14 days
Of the 418 patients who completed testing and had micro-
biologically-confirmed TB, 313 (74.9%; 95% CI: 69.9–80.2%) were
initiated on TB treatment within 14 days of presenting to the health
center (Fig. 3). This ranged across health centers from 14.3% to 100%
(Fig. 4), and across months from 50.0% to 92.7% (Fig. 5). Of the re-
maining patients, 88 (21.1%) never started treatment and 17 (4.1%)
started treatment between 15 and 48 days of presenting to the health
center.
3.3.4. ISTC-recommended care
Of the 6744 patients with presumptive TB, 2873 received ISTC-
adherent care. The proportion who received ISTC-recommended care
was 42.6% (95% CI: 37.2–48.7%) overall (Fig. 3) and ranged across
health centers from 15.7% to 64.0% (Fig. 4). The range across months
was 29.5%–50.9% (Fig. 5).
4. Discussion
Considerable resources have been devoted to scaling-up Xpert de-
vices and cartridges in high TB burden countries, with many countries
achieving high coverage. However, little attention has been paid to the
impact of scale-up on the utilization of Xpert and quality of care for
patients with presumptive TB, particularly at lower-level facilities
without onsite Xpert testing capacity. At health centers linked to Xpert
testing hubs across Uganda, we found that there was limited uptake of
Xpert testing. Less than one-quarter of all patients and only 33.3% of
patients with known HIV infection had samples referred for Xpert
testing, and only 52.9% of patients confirmed to have TB by Xpert
testing were initiated on treatment rapidly (within 14 days). Adherence
to ISTC guidelines for TB diagnostic evaluation was poor, with less than
half of patients receiving guideline-recommended care. Additional
Fig. 4. Health center-level variation in quality of TB diagnostic evaluation (January–December 2017). The graph plots each quality indicator for the 24 health
centers, along with the summary estimate and 95% confidence interval adjusted for health center. Each circle represents the relative size of each health center by
indicator. Across the health centers, the proportions with samples referred for TB testing, completing test if referred, initiating treatment if TB was confirmed and
receiving ISTC-recommended care varied from 58.7–92.0%, 20.9–80.8%, 14.3–100%, and 15.7–64.0%, respectively.
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attention and resources are needed to ensure that high coverage of
Xpert testing capacity translates into improvements in patient care.
Our findings are consistent with previous studies suggesting low
uptake of Xpert testing. Hanrahan et al. also found Xpert utilization to
be poor in Uganda, with only 21% of smear-negative patients receiving
Xpert testing at 18 health centers, of which eight had onsite Xpert
testing capacity [10]. Clouse et al. studied Xpert utilization among HIV/
TB co-infected adults in 18 countries and found that <15% received
Xpert testing even when onsite testing was available [11]. To our
knowledge, however, our study is the first to assess the entire cascade of
care for TB diagnostic evaluation, from referral for TB testing to TB
treatment initiation for patients who test positive, in the context of
Xpert scale-up. If generated in real-time, such data could be used to
drive facility-level quality improvement.
Our study demonstrates that quality of care for patients undergoing
TB evaluation remains poor despite high coverage of Xpert devices and
cartridges. The vast majority of patients had samples referred for
sputum smear examination as the first-line test, regardless of HIV
status. When sputum was collected and sent for Xpert testing, a valid
result was obtained for 97.7% of patients. However, there were sig-
nificant delays in testing and notification of results, leading to only
52.9% of patients confirmed to have TB by Xpert testing being treated
within 14 days and 37.0% not initiating treatment. In contrast, the vast
majority (83.6%) of smear-positive TB patients initiated treatment at
their initial health center visit.
This study has several potential limitations. First, we focus on im-
pact of Xpert scale-up on diagnosis and treatment of drug susceptible
TB. Although rapid identification of patients with likely MDR TB is a
major advantage of Xpert testing, only two patients were found to have
RIF-resistance in our study. Both patients were referred to an MDR TB
treatment center and initiated MDR TB treatment within twelve days.
Second, it is possible that our pragmatic data collection methods re-
sulted in underestimation of Xpert utilization and its impact on quality
of care. We believe this is unlikely as any Xpert testing missed through
review of TB registers at the health centers was captured through re-
view of the national GxAlert database. Finally, while our study high-
lights key gaps in the quality of care, further mixed methods research is
needed to identify health system-, provider- and patient-level factors
contributing to the gaps [12].
In summary, despite massive scale-up of Xpert testing capacity in
Uganda, quality of care remains poor at peripheral TB diagnostic units.
Funding agencies and National TB Programs in low- and middle- in-
come countries should focus resources not just on procuring GeneXpert
devices and Xpert cartridges, but also on ensuring that testing and
communication of results to providers and patients occurs rapidly.
Implementation and operational research is needed to identify barriers
to rapid testing and treatment initiation. The development and testing
of interventions to overcome these barriers will allow the scale-up of
novel diagnostics to realize its full potential.
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